• Pharma Technology Focus – Issue 70

    In this issue: A toolkit to enhance the user experience for life sciences, the problem of unapproved antibiotics in India, a new taxonomy for traditional Chinese medicine, inside Canada’s Centre...

  • Pharma Technology Focus – Issue 69

    In this issue: The world’s pharma manufacturing hotspots, creating a universal flu vaccine, obstacles to improving the treatment of Alzheimer’s disease, the potential of growth drugs, detecting racemisation in drugs,...

  • Turning up the heat on nano research

    Scientists from the University of Surrey have developed nanoparticles that heat up to a temperature high enough to kill cancerous cells. They also cleverly self-regulate to cool down before they...

  • Block and lock: a functional cure for HIV?

    New research has opened the door to a completely different approach to tackling HIV infections. Elly Earls meets lead author of the study, Susana Valente, to find out more.

  • Is a universal flu vaccine on the horizon?

    Oxford University spin-out company Vaccitech is trialling what it hopes will be a more effective, universal flu vaccine. The company recently raised £20m from investors including Google parent firm Alphabet,...

  • Cracking the mysteries of Alzheimer’s disease

    With Pfizer shutting down its neuroscience unit and a long list of failed late-stage trials, the sheer difficulty of improving the treatment of Alzheimer’s disease has become painfully clear. How...

  • Fentanyl: where did it all go wrong?

    Fentanyl, a powerful opioid painkiller developed in the early 1960s, has been an important part of pain management strategies for decades, but a recent explosion of fentanyl abuse has had...

  • Using mRNa to target tumours

    Eli Lilly recently announced it is investing $1.8bn in a project with CureVac to develop mRNA cancer vaccines. While their work is still at an early stage, research suggests that...

  • Pharma Technology Focus – Issue 67

    In this issue: How cancer drug resistance works, accessing funding for rare diseases, India’s attempt to redefine over the counter drugs, the biotech potential of slipper limpets, Dundee University’s influence...